Reuters: IPOX® CEO Josef Schuster on Heartflow's IPO and the Medtech Rebound

In a recent Reuters article, medical technology company Heartflow's plan to go public was discussed with input from IPOX® CEO Josef Schuster, highlighting a potential rebound in the medtech IPO market. The company, backed by Bain Capital, is targeting a valuation of up to $1.32 billion in its U.S. initial public offering. This move follows several other successful medtech listings in 2025, signaling renewed investor interest in the sector after a prolonged downturn.

Dr. Schuster was quoted in the piece, offering his expert analysis on Heartflow's prospects. He noted the company's favorable position for attracting initial investors, stating, "Heartflow's strong top-line growth and high gross margins position it well for initial investor interest, especially given its similarity to commercialized Beta Bionics and Kestra Medical."

Schuster also provided a note of caution regarding the broader market environment. "Still, with broader market volatility rising and select deals trading below offer, investors may be cautious beyond the first trading day," he added.

Read the full article by Arasu Kannagi Basil on Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/bain-capital-backed-heartflow-eyes-132-billion-valuation-medtech-ipos-rebound-2025-08-01/